Not applicableEnded earlyNCT01067742What this trial is testingThe Natural History of Mucolipidosis Type IVWho this might be right forMucolipidosis Type IV Baylor Research Institute 7
Not applicableWithdrawnNCT02385162What this trial is testingBiomarker for Glycogen Storage Diseases (BioGlycogen)Who this might be right forFructose Metabolism, Inborn ErrorsGlycogen Storage DiseaseGlycogen Storage Disease Type I+7 more CENTOGENE GmbH Rostock
Early research (Phase 1)Enrolling By InvitationNCT07398872What this trial is testingSafety and Efficacy of AAV9. hMCOLN1co For Patients With Mucolipidosis Type IVWho this might be right forMucolipidosis Type IV The Children's Hospital of Zhejiang University School of Medicine 1
Not applicableWithdrawnNCT02298673What this trial is testingBiomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML)Who this might be right forSkeletal AbnormalitiesPsychomotor Retardation CENTOGENE GmbH Rostock
Early research (Phase 1)Study completedNCT02434861What this trial is testingAn Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (2 mg/mL IV Solution) on the Pharmacokinetics of Digoxin; Sulfasalazine; and the Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan in Healthy SubjectsWho this might be right forChemotherapy-induced Nausea and Vomiting Tesaro, Inc. 102
Not applicableLooking for participantsNCT01793168What this trial is testingRare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at SanfordWho this might be right forRare DisordersUndiagnosed DisordersDisorders of Unknown Prevalence+340 more Sanford Health 20,000
Not applicableLooking for participantsNCT05782387What this trial is testingMucolipidosis Type IV Natural History StudyWho this might be right forMucolipidosis Type IV Massachusetts General Hospital 50
Not applicableStudy completedNCT00015782What this trial is testingThe Natural History and Pathogenesis of Mucolipidosis Type IVWho this might be right forMucolipidosis Type IV National Institute of Neurological Disorders and Stroke (NINDS) 30